Business
DRI Healthcare Trust Announces Acquisition of a Royalty Interest in Zejula®, Currently Approved for the Treatment of Ovarian Cancer with Additional Indications Under Development
DRI Healthcare Trust Announces Acquisition of a Royalty Interest in Zejula®, Current...
About this update from Dri Healthcare Trust
[{"type":"text","content":"\n \n \n \n DRI Healthcare Trust Announces Acquisition of a Royalty Interest in Zejula®, Currently Approved for the Treatment of Ovarian Cancer with Additional Indications Under Development\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n – Zejula's multiple pipeline indications offer significant upside potential –\n \n \n \n \n – Transaction builds on DRI's history of investing in innovative oncology therapies –\n \n \n \n \n – Long-term asset with strong intellectual property protection –\n \n \n \n \n \n TORONTO\n \n \n ,\n \n \n Sept. 12, 2022\n \n \n /CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (\"DRI\" or \"the Trust\") today announced that a wholly-owned subsidiary of DRI has acquired a royalty interest in Zejula from AnaptysBio, Inc. for a purchase price of\n \n US$35 million\n \n . An additional milestone payment of\n \n US$10 million\n \n will be paid should Zejula be approved by the U.S. Food and Drug Administration (\"FDA\") for the treatment of endometrial cancer on or before\n \n December 31, 2025\n \n .\n \n \n \n \n \n \n \n \n \n Zejula is approved by both the FDA and European Medicines Agency (\"EMA\") as a treatment for both first-line and recurrent ovarian cancer. Additional indications in development include endometrial cancer, HER2-negative breast cancer, non-small cell lung cancer, metastatic castrate-sensitive prostate cancer, as well as metastatic castration-resistant prostate cancer, which was submitted for approval to the EMA in\n \n April 2022\n \n .\n \n \n \"We are excited to announce the addition of Zejula to our portfolio,\" said\n \n Behzad Khosrowshahi\n \n , Chief Executive Officer of DRI Healthcare Trust. \"Our expanding expertise in oncology products helped us identify a versatile product with multiple pipeline indications that present significant potential sales growth. This accretive transaction adds another long-term asset, providing immediate cash flows to the Trust with significant growth potentia...